| Biomarker ID | 1244 |
| PMID | 24240687 |
| Year | 2013 |
| Biomarker | N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated with High Tumor Stage |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: SGK494 human kinase ARCHS4 coexpression, SCYL3 human kinase ARCHS4 coexpression, AURKC human kinase ARCHS4 coexpression, BMPR1B human kinase ARCHS4 coexpression, RPS6KA5 human kinase ARCHS4 coexpression |
| Experiment | Tumor Stage pT2 Vs pT3 Vs pT4 |
| Type of Biomarker | Prognostic |
| Cohort | 222 Benign Tissues along with 511 Prostate Cancer tissues were chosen for evaluation. Out of 511 cancerous tissue, 224 had Tumor Stage pT2, 188 had pT3, 5 had pT4 |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p= 0.004 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NAALADL2 |